<DOC>
	<DOCNO>NCT02210546</DOCNO>
	<brief_summary>A multicenter randomize control trial evaluate performance MRI , term sensitivity , specificity , predictive value , screen woman intermediate risk breast cancer . Two surveillance program compare . Women randomly assign 1:1 ratio : 1 . Yearly two-view mammography ( Mx ) breast ultrasonography ( US ) 2 . Yearly MRI .</brief_summary>
	<brief_title>Contrast-enhanced MR Imaging Breast Cancer Screening Women Intermediate Risk</brief_title>
	<detailed_description>Women , , due increase risk invasive breast cancer , offer specific surveillance program , supplement standard screening activity Italy base mammography every two year start age 50.Women randomly assign Yearly two-view mammography ( Mx ) breast ultrasonography ( US ) Yearly MRI .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women age 4059 year cumulative risk 10 year least 5 % , lifetime cumulative breast cancer risk range 15 % 30 % ( equivalent relative risk 26 compare low risk woman age ) . The lifetime cumulative risk breast cancer compute use IBIS Breast Cancer Risk Evaluation Tool ( http : //www.emstrials.org/riskevaluator/ ) ; mammographic density involve 75 % breast area , base recent mammogram . The evaluation composition mammary gland perform use BIRADS classification . Women mammography class 4 ( i.e. , &gt; 75 % glandular component ) eligible randomization . Written Informed consent Signs symptom breast cancer enrolment ; Previous diagnosis ductal carcinoma situ invasive breast cancer ; BRCA p53 mutation carrier status ; General contraindication MRI ( e.g . cardiac pacemaker , metal implant history severe allergic reaction administration contrast agent ; Contraindications intravenous administration contrast agent ; Ongoing plan pregnancy ( duration study ) ; Hormonal enhancement ovarian function assist reproduction previous 3 year Presence breast implant ; Previous diagnosis cancer site ; Lifethreatening diseases ; Mental disability preclude informed consent participate</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>intermediate risk</keyword>
</DOC>